Cipla And mAbxience Partner For Essential Biosimilars In South Africa
Partners Will Focus On Oncology And Respiratory-Related Biosimilars
Executive Summary
Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.
You may also be interested in...
Alvotech And Cipla Strike Biosimilars Alliance In South Africa
Alvotech, fresh from a round of financing, has grand plans to market its biosimilar candidates across the globe. A new partnership just signed with South Africa-based Cipla Medpro will cover five candidates, including two in oncology.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.
British Columbia Adds Three Anti-Clotting Biosimilars To PharmaCare
British Columbia has added three new biosimilar versions of the anti-clotting drug enoxaparin to PharmaCare, including Redesca, Noromby and Inclunox. The move comes after the Canadian province recently included additional biosimilars in its switching program.